P
Paul Bryan Wren
Researcher at GlaxoSmithKline
Publications - 15
Citations - 972
Paul Bryan Wren is an academic researcher from GlaxoSmithKline. The author has contributed to research in topics: Stimulation & Rolipram. The author has an hindex of 8, co-authored 15 publications receiving 817 citations.
Papers
More filters
Journal ArticleDOI
BDNF-based synaptic repair as a disease-modifying strategy for neurodegenerative diseases
TL;DR: The key issues in translating BDNF biology into synaptic repair therapies are reviewed, which pave the way for a 'synaptic repair' therapy for neurodegenerative diseases that targets pathophysiology rather than pathogenesis.
Journal ArticleDOI
Mechanistic and Pharmacological Characterization of PF-04457845: A Highly Potent and Selective Fatty Acid Amide Hydrolase Inhibitor That Reduces Inflammatory and Noninflammatory Pain
Kay Ahn,Sarah E. Smith,Marya Liimatta,David Beidler,Nalini Sadagopan,David T. Dudley,Tim Young,Paul Bryan Wren,Yanhua Zhang,Steven Swaney,Keri Van Becelaere,Jacqueline L. Blankman,Daniel K. K. Nomura,Shoba N. Bhattachar,Cory Michael Stiff,Tyzoon K. Nomanbhoy,Eranthie Weerapana,Douglas S. Johnson,Benjamin F. Cravatt +18 more
TL;DR: Based on its exceptional selectivity and in vivo efficacy, combined with long duration of action and optimal pharmacokinetic properties, PF-04457845 is a clinical candidate for the treatment of pain and other nervous system disorders.
Journal ArticleDOI
GSK356278, a Potent, Selective, Brain-Penetrant Phosphodiesterase 4 Inhibitor That Demonstrates Anxiolytic and Cognition-Enhancing Effects without Inducing Side Effects in Preclinical Species
A. Richard Rutter,Alessandro Poffe,Palmina Cavallini,T. Gregg Davis,Jessica L. Schneck,Michele Negri,Elena Vicentini,Dino Montanari,Roberto Arban,Frank A Gray,Ceri H. Davies,Paul Bryan Wren +11 more
TL;DR: GSK356278 is described as a potent, selective, and brain-penetrant PDE4 inhibitor that shows a superior therapeutic index to both rolipram and roflumilast in various preclinical species and has potential for further development in the clinic for the treatment of psychiatric and neurologic diseases.
Journal ArticleDOI
Astrocyte reactivity with late-onset cognitive impairment assessed in vivo using 11C-BU99008 PET and its relationship with amyloid load
Valeria Calsolaro,Paul M. Matthews,Cornelius K. Donat,Nicholas R Livingston,Grazia Daniela Femminella,Sandra Silva Guedes,Jim Myers,Zhen Fan,Robin J. Tyacke,Ashwin V. Venkataraman,Robert Perneczky,Roger N. Gunn,Eugenii A. Rabiner,Steve M. Gentleman,Christine A. Parker,Christine A. Parker,Philip S. Murphy,Paul Bryan Wren,Rainer Hinz,Magdalena Sastre,David J. Nutt,Paul Edison,Paul Edison +22 more
TL;DR: In this paper, a PET tracer called 11C-BU99008 was used to measure in vivo astrocyte reactivity in people with late-life cognitive impairment and Alzheimer's disease.
Journal ArticleDOI
The Identification of a Novel Phosphodiesterase 4 Inhibitor, 1-Ethyl-5-{5-[(4-methyl-1-piperazinyl)methyl]-1,3,4-oxadiazol-2-yl}-N-(tetrahydro-2H-pyran-4-yl)-1H-pyrazolo[3,4-b]pyridin-4-amine (EPPA-1), with Improved Therapeutic Index using Pica Feeding in Rats as a Measure of Emetogenicity
T. Gregg Davis,John J. Peterson,Jen-Pyng Kou,Elizabeth A. Capper-Spudich,Doug Ball,Anthony T. Nials,Joanne O. Wiseman,Yemisi E. Solanke,Fiona S. Lucas,Richard A. Williamson,Livia Ferrari,Paul Bryan Wren,Richard G. Knowles,Mary S. Barnette,Patricia L. Podolin +14 more
TL;DR: In vitro and in vivo anti-inflammatory potencies of the first-generation PDE4 inhibitor, rolipram, the second-generation inhibitors, roflumilast and cilomilast, and a novel third generation inhibitor are determined and EPPA-1 is identified as a novel PDE 4 inhibitor with an improved therapeutic index.